Tumor Lysate Loaded Particles for Robust Anti-Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Previous methods for presenting tumor antigens to the immune system through the MHC class I pathway for eliciting a robust anti-tumor immunity are limited, as they struggle to identify all important tumor-specific antigens, map specific antigen genes, introduce only a few known antigen genes into dendritic cells, and are time-consuming and cumbersome.
Innovation Solution
Isolated dendritic cells loaded with tumor lysate particles, specifically yeast cell wall particles, are used, where the tumor lysate is loaded into the particles, freeze-dried, and incubated with dendritic cells to induce phagocytosis, potentially enhanced with immune response adjuvants to stimulate a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene transfer methods are used to present tumor antigens through the MHC class I pathway, then CD8+ T cells are activated, but the ability to identify all important tumor-specific antigens is limited and the process is time-consuming
Solution Approach 1:
The patent extracts tumor antigens directly from tumor lysate and loads them onto particles, bypassing the need for gene identification, mapping, and transfer methods. This extraction approach allows comprehensive antigen presentation without the limitations of gene-by-gene analysis, significantly accelerating the process while maintaining robust CD8+ T cell activation
Solution Approach 2:
The patent introduces particles as an intermediary carrier to deliver tumor lysate antigens to dendritic cells. This mediator approach enables direct antigen presentation through MHC class I pathway without requiring complex gene transfer procedures, resolving the contradiction between reliability of immune response and productivity of antigen processing
2Ease of manufacture
If only a small number of known tumor antigen genes are introduced into dendritic cells, then the process is simplified, but the ability to present all important tumor antigens is limited
Solution Approach 1:
The patent uses particles with universal capacity to carry and deliver comprehensive tumor lysate containing all tumor antigens, rather than limiting to specific known antigen genes. This universal approach maintains ease of manufacture through simple particle loading while achieving complete antigen presentation across all tumor-specific antigens
Solution Approach 2:
The patent creates a comprehensive copy of the tumor antigen repertoire by loading entire tumor lysate onto particles, preserving all tumor-specific antigens without selective limitation. This copying approach simplifies the manufacturing process compared to individual gene introduction while ensuring complete antigen coverage for robust immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively activates CD8+ T cells and generates a more robust immune response against tumor cells, demonstrating significant anti-tumor immunity in preclinical models, with the potential to treat various cancers.
Implementation Method 1
incubating the tumor lysate loaded particle with a dendritic cell, wherein the incubating causes the dendritic cell to phagocytose the tumor lysate loaded particle
Implementation Method 2
freeze-drying the tumor lysate loaded particle
Data Source
AI summary
Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.